Letaplimab represents a unique clinical approach for addressing complement-mediated diseases. This biologic targets the C1q protein, a key component of the complement pathway, aiming to disrupt its initial activation. https://shaniapern586621.pointblog.net/letaplimab-a-innovative-therapeutic-method-93065282